Logo image of RXST

RXSIGHT INC (RXST) Stock Fundamental Analysis

NASDAQ:RXST - Nasdaq - US78349D1072 - Common Stock - Currency: USD

14.98  +0.26 (+1.77%)

After market: 14.86 -0.12 (-0.8%)

Fundamental Rating

4

Overall RXST gets a fundamental rating of 4 out of 10. We evaluated RXST against 189 industry peers in the Health Care Equipment & Supplies industry. The financial health of RXST is average, but there are quite some concerns on its profitability. RXST is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

RXST had negative earnings in the past year.
RXST had a negative operating cash flow in the past year.
RXST had negative earnings in 4 of the past 5 years.
In the past 5 years RXST always reported negative operating cash flow.
RXST Yearly Net Income VS EBIT VS OCF VS FCFRXST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

RXST has a Return On Assets of -8.62%. This is in the better half of the industry: RXST outperforms 62.43% of its industry peers.
The Return On Equity of RXST (-9.76%) is better than 65.61% of its industry peers.
Industry RankSector Rank
ROA -8.62%
ROE -9.76%
ROIC N/A
ROA(3y)-26.56%
ROA(5y)-20.32%
ROE(3y)-38.11%
ROE(5y)-28.71%
ROIC(3y)N/A
ROIC(5y)N/A
RXST Yearly ROA, ROE, ROICRXST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

With an excellent Gross Margin value of 70.71%, RXST belongs to the best of the industry, outperforming 80.42% of the companies in the same industry.
RXST's Gross Margin has improved in the last couple of years.
RXST does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 70.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y52.32%
GM growth 5YN/A
RXST Yearly Profit, Operating, Gross MarginsRXST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 1K -1K -2K

More info and screens

6

2. Health

2.1 Basic Checks

RXST does not have a ROIC to compare to the WACC, probably because it is not profitable.
RXST has more shares outstanding than it did 1 year ago.
The number of shares outstanding for RXST has been increased compared to 5 years ago.
Compared to 1 year ago, RXST has an improved debt to assets ratio.
RXST Yearly Shares OutstandingRXST Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
RXST Yearly Total Debt VS Total AssetsRXST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 7.94 indicates that RXST is not in any danger for bankruptcy at the moment.
RXST's Altman-Z score of 7.94 is amongst the best of the industry. RXST outperforms 89.95% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that RXST is not too dependend on debt financing.
The Debt to Equity ratio of RXST (0.00) is better than 69.31% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.94
ROIC/WACCN/A
WACC8.83%
RXST Yearly LT Debt VS Equity VS FCFRXST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

RXST has a Current Ratio of 11.36. This indicates that RXST is financially healthy and has no problem in meeting its short term obligations.
RXST has a Current ratio of 11.36. This is amongst the best in the industry. RXST outperforms 94.71% of its industry peers.
A Quick Ratio of 10.50 indicates that RXST has no problem at all paying its short term obligations.
RXST has a better Quick ratio (10.50) than 93.65% of its industry peers.
Industry RankSector Rank
Current Ratio 11.36
Quick Ratio 10.5
RXST Yearly Current Assets VS Current LiabilitesRXST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 47.83% over the past year.
The Revenue has grown by 57.08% in the past year. This is a very strong growth!
The Revenue has been growing by 128.63% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)47.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.31%
Revenue 1Y (TTM)57.08%
Revenue growth 3Y83.65%
Revenue growth 5Y128.63%
Sales Q2Q%40.71%

3.2 Future

Based on estimates for the next years, RXST will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.74% on average per year.
Based on estimates for the next years, RXST will show a very strong growth in Revenue. The Revenue will grow by 20.29% on average per year.
EPS Next Y6.59%
EPS Next 2Y14.94%
EPS Next 3Y18.74%
EPS Next 5YN/A
Revenue Next Year21.65%
Revenue Next 2Y21.56%
Revenue Next 3Y21.27%
Revenue Next 5Y20.29%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
RXST Yearly Revenue VS EstimatesRXST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M 200M 250M
RXST Yearly EPS VS EstimatesRXST Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RXST. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RXST. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RXST Price Earnings VS Forward Price EarningsRXST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RXST Per share dataRXST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

A more expensive valuation may be justified as RXST's earnings are expected to grow with 18.74% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.94%
EPS Next 3Y18.74%

More info and screens

0

5. Dividend

5.1 Amount

RXST does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RXSIGHT INC

NASDAQ:RXST (5/1/2025, 4:39:46 PM)

After market: 14.86 -0.12 (-0.8%)

14.98

+0.26 (+1.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-25 2025-02-25/amc
Earnings (Next)05-07 2025-05-07/amc
Inst Owners91.05%
Inst Owner Change0.12%
Ins Owners5.07%
Ins Owner Change-0.02%
Market Cap608.49M
Analysts83.75
Price Target25.6 (70.89%)
Short Float %9.53%
Short Ratio4.15
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.68%
Min EPS beat(2)11.05%
Max EPS beat(2)36.3%
EPS beat(4)4
Avg EPS beat(4)21.26%
Min EPS beat(4)7.94%
Max EPS beat(4)36.3%
EPS beat(8)8
Avg EPS beat(8)23.2%
EPS beat(12)12
Avg EPS beat(12)20.43%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-1.74%
Min Revenue beat(2)-2.21%
Max Revenue beat(2)-1.26%
Revenue beat(4)2
Avg Revenue beat(4)1.87%
Min Revenue beat(4)-2.21%
Max Revenue beat(4)5.95%
Revenue beat(8)6
Avg Revenue beat(8)3.17%
Revenue beat(12)10
Avg Revenue beat(12)5.4%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-45.57%
PT rev (3m)-56.72%
EPS NQ rev (1m)-9.5%
EPS NQ rev (3m)-32.79%
EPS NY rev (1m)-23.63%
EPS NY rev (3m)-75.04%
Revenue NQ rev (1m)-4.25%
Revenue NQ rev (3m)-7.77%
Revenue NY rev (1m)-10.38%
Revenue NY rev (3m)-10.13%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.35
P/FCF N/A
P/OCF N/A
P/B 2.16
P/tB 2.16
EV/EBITDA N/A
EPS(TTM)-0.72
EYN/A
EPS(NY)-0.67
Fwd EYN/A
FCF(TTM)-0.55
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS3.44
BVpS6.92
TBVpS6.92
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.62%
ROE -9.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 70.71%
FCFM N/A
ROA(3y)-26.56%
ROA(5y)-20.32%
ROE(3y)-38.11%
ROE(5y)-28.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y52.32%
GM growth 5YN/A
F-Score5
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 150.11%
Cap/Sales 3.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.36
Quick Ratio 10.5
Altman-Z 7.94
F-Score5
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)107.67%
Cap/Depr(5y)87%
Cap/Sales(3y)4.72%
Cap/Sales(5y)8.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.31%
EPS Next Y6.59%
EPS Next 2Y14.94%
EPS Next 3Y18.74%
EPS Next 5YN/A
Revenue 1Y (TTM)57.08%
Revenue growth 3Y83.65%
Revenue growth 5Y128.63%
Sales Q2Q%40.71%
Revenue Next Year21.65%
Revenue Next 2Y21.56%
Revenue Next 3Y21.27%
Revenue Next 5Y20.29%
EBIT growth 1Y26.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year49.6%
EBIT Next 3Y35.21%
EBIT Next 5YN/A
FCF growth 1Y51.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y59.26%
OCF growth 3YN/A
OCF growth 5YN/A